640-79-9
640-79-9
Chemical Structure
Glycochenodeoxycholic acid
Synonym(s): Chenodeoxycholylglycine
- CAS No.: 640-79-9
- Formula:C26H43NO5
- Molecular Weight:449.62
IUPAC Name: ((R)-4-((3R,5S,7R,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoyl)glycine
InChIKey: GHCZAUBVMUEKKP-GYPHWSFCSA-N
SMILES: C[C@@]12[C@](CC[C@]2([H])[C@H](C)CCC(NCC(O)=O)=O)([H])[C@@]3([H])[C@]([C@@]4([C@](C[C@H](O)CC4)([H])C[C@H]3O)C)([H])CC1
Biological Activity: Glycochenodeoxycholic acid (Chenodeoxycholylglycine) is a relatively toxic bile salt generated in the liver from chenodeoxycholic acid and glycine. Glycochenodeoxycholic acid inhibits Autophagosome formation and impairs lysosomal function by inhibiting lysosomal proteolysis and increasing lysosomal pH in human normal liver cells, leading to the Apoptosis of human hepatocyte cells. Glycochenodeoxycholic acid induces stemness and chemoresistance via activating STAT3 signaling pathway in hepatocellular carcinoma cells (HCC). Glycochenodeoxycholic acid is promising for research in the field of cholestasis desease, hepatocellular carcinoma and primary sclerosing cholangitis (PSC)[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Glycochenodeoxycholic acid | 99.96% | Glycochenodeoxycholic acid (Chenodeoxycholylglycine) is a relatively toxic bile salt generated in the liver from chenodeoxycholic acid and glycine. Glycochenodeoxycholic acid inhibits Autophagosome formation and impairs lysosomal function by inhibiting lysosomal proteolysis and increasing lysosomal pH in human normal liver cells, leading to the Apoptosis of human hepatocyte cells. Glycochenodeoxycholic acid induces stemness and chemoresistance via activating STAT3 signaling pathway in hepatocellular carcinoma cells (HCC). Glycochenodeoxycholic acid is promising for research in the field of cholestasis desease, hepatocellular carcinoma and primary sclerosing cholangitis (PSC). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Glycochenodeoxycholic acid (Standard) | 99.77% | Glycochenodeoxycholic acid (Standard) is the analytical standard of Glycochenodeoxycholic acid. This product is intended for research and analytical applications. Glycochenodeoxycholic acid (Chenodeoxycholylglycine) is a relatively toxic bile salt generated in the liver from chenodeoxycholic acid and glycine. Glycochenodeoxycholic acid inhibits Autophagosome formation and impairs lysosomal function by inhibiting lysosomal proteolysis and increasing lysosomal pH in human normal liver cells, leading to the Apoptosis of human hepatocyte cells. Glycochenodeoxycholic acid induces stemness and chemoresistance via activating STAT3 signaling pathway in hepatocellular carcinoma cells (HCC). Glycochenodeoxycholic acid is promising for research in the field of cholestasis desease, hepatocellular carcinoma and primary sclerosing cholangitis (PSC). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Glycochenodeoxycholic acid-d4 | 99.95% | Glycochenodeoxycholic acid-d4 is the deuterium labeled Glycochenodeoxycholic acid. Glycochenodeoxycholic acid (Chenodeoxycholylglycine) is a bile acid formed in the liver from chenodeoxycholate and glycine. It acts as a detergent to solubilize fats for absorption and is itself absorbed. Glycochenodeoxycholic acid (Chenodeoxycholylglycine) induces hepatocyte apoptosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ursodeoxycholic acid-d4 | 99.52% | Ursodeoxycholic acid-2,2,4,4-d4 is the deuterium labeled Ursodeoxycholic acid (HY-13771). Ursodeoxycholic acid is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Glycolithocholic acid-d4 | 99.37% | Glycolithocholic acid-d4 is the deuterium labeled Glycolithocholic acid. Glycolithocholic acid, an endogenous metabolite, is a glycine-conjugated secondary bile acid and can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) . | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Glycodeoxycholic acid-d4 | 99.78% | Glycodeoxycholic acid-d4 is the deuterium labeled Glycodeoxycholic Acid. Glycodeoxycholic Acid is an endogenous metabolite. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Glycohyodeoxycholic acid (Standard) | 99.89% | Glycohyodeoxycholic acid (Standard) is the analytical standard of Glycohyodeoxycholic acid. This product is intended for research and analytical applications. Glycohyodeoxycholic acid is a glycine-conjugated bile acid and also a metabolite of Hyodeoxycholic acid (HY-N0169). The serum level of Glycohyodeoxycholic acid is negatively correlated with the severity of non-alcoholic fatty liver disease. Glycohyodeoxycholic acid can be used in research related to non-alcoholic fatty liver disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Glyco-Obeticholic acid | 98.80% | Glyco-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is a farnesoid X receptor (FXR) agonist. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ursodeoxycholic acid | 99.94% | Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ursodeoxycholic acid-13C | Ursodeoxycholic acid-13C is the 13C labeled Ursodeoxycholic acid. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Taurochenodeoxycholic acid-d4 | Taurochenodeoxycholic acid-d4 (TCDCA-d4) is the deuterium labeled Taurochenodeoxycholic acid. Taurochenodeoxycholic acid (12-Deoxycholyltaurine) is one of the main bioactive substances of animals' bile acid. Taurochenodeoxycholic acid induces apoptosis and shows obvious anti-inflammatory and immune regulation properties. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Allochenodeoxycholic acid | 99.94% | Allochenodeoxycholic acid is a nucleoside metabolite. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tauroursodeoxycholate-d4 sodium | 99.34% | Tauroursodeoxycholate-d4 (sodium) is the deuterium labeled Tauroursodeoxycholate sodium. Tauroursodeoxycholate (Tauroursodeoxycholic acid; TUDCA) sodium is an endoplasmic reticulum (ER) stress inhibitor. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as caspase-3 and caspase-12. Tauroursodeoxycholate also inhibits ERK. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tauroursodeoxycholate-d4 | 99.70% | Tauroursodeoxycholate-d4 is deuterium labeled Tauroursodeoxycholate. Tauroursodeoxycholate (Tauroursodeoxycholic acid) is an endoplasmic reticulum (ER) stress inhibitor. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as caspase-3 and caspase-12. Tauroursodeoxycholate also inhibits ERK. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Chenodeoxycholic Acid | 99.93% | Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Chenodeoxycholic Acid-d4 | 99.94% | Chenodeoxycholic Acid-d4 is the deuterium labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Chenodeoxycholic acid-13C | 98.0% | Chenodeoxycholic acid-13C is the 13C-labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Glycochenodeoxycholic acid 3-sulfate-d4 | Glycochenodeoxycholic acid 3-sulfate-d4 (GCDCA-S-d4; 3-Sulfate-GCDCA-d4) is the deuterated-labeled Glycochenodeoxycholic acid 3-sulfate (HY-N12462). Glycochenodeoxycholic acid 3-sulfate (GCDCA-S; 3-Sulfate-GCDCA) is an endogenous sulfated bile acid metabolite and a substrate of OATP1B1/OATP1B3. Glycochenodeoxycholic acid 3-sulfate serves as a candidate endogenous biomarker for renal OAT1/OAT3 and is also a biomarker of endogenous OAT-mediated renal secretion and OAT inhibition. Glycochenodeoxycholic acid 3-sulfate can be used in research on metabolism-related diseases. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Glycocholic acid (Standard) | 99.90% | Glycocholic acid (Standard) is the analytical standard of Glycocholic acid (HY-N1423). This product is intended for research and analytical applications. Glycocholic acid is a bile acid with anticancer activity, targeting against pump resistance-related and non-pump resistance-related pathways. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Glycocholic acid-d4 | 99.92% | Glycocholic acid-d4 is the deuterium labeled Glycocholic acid (HY-N1423). Glycocholic acid is a bile acid derivative. Glycocholic acid downregulates MDR1, Bcl-2, MRP1, MRP2 and FXR, upregulates Bax, p53, caspase-9, caspase-3, TGR5 and S1PR2. Glycocholic acid inhibits multidrug resistance and efflux pumps, induces mitochondrial apoptosis, and enhances chemosensitivity. Glycocholic acid modulates related bile acid receptor signaling. Glycocholic acid suppresses growth and conjugation of Enterobacteriaceae and increases their antibiotic susceptibility. Glycocholic acid can be used for the research of colon adenocarcinoma and cholangiocarcinoma (CCA). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Glycoursodeoxycholic acid | 99.80% | Glycoursodeoxycholic acid, a acyl glycine and a bile acid-glycine conjugate, is a metabolite of ursodeoxycholic acid. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Glycoursodeoxycholic acid-d4 | 99.78% | Glycoursodeoxycholic acid-d4 (Ursodeoxycholylglycine-d4) is the deuterium labeled Glycoursodeoxycholic acid. Glycoursodeoxycholic acid, a acyl glycine and a bile acid-glycine conjugate, is a metabolite of ursodeoxycholic acid. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Glycochenodeoxycholic acid sodium salt (Standard) | 99.75% | Glycochenodeoxycholic acid sodium salt (Standard) is the analytical standard of Glycochenodeoxycholic acid sodium salt. This product is intended for research and analytical applications. Glycochenodeoxycholic acid sodium salt (Sodium glycochenodeoxycholate) is a relatively toxic bile salt generated in the liver from chenodeoxycholic acid and glycine. Glycochenodeoxycholic acid sodium salt inhibits Autophagosome formation and impairs lysosomal function by inhibiting lysosomal proteolysis and increasing lysosomal pH in human normal liver cells, leading to the Apoptosis of human hepatocyte cells. Glycochenodeoxycholic acid sodium salt induces stemness and chemoresistance via activating STAT3 signaling pathway in hepatocellular carcinoma cells (HCC). Glycochenodeoxycholic acid sodium salt is promising for research in the field of cholestasis desease, hepatocellular carcinoma and primary sclerosing cholangitis (PSC). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Lan W, et al. Glycochenodeoxycholic acid impairs transcription factor E3 -dependent autophagy-lysosome machinery by disrupting reactive oxygen species homeostasis in L02 cells[J]. Toxicol Lett. 2020 Oct 1;331:11-21. [Content Brief]
- [2]. Wang A, et al. Glycochenodeoxycholic Acid Does Not Increase Transforming Growth Factor-Beta Expression in Bile Duct Epithelial Cells or Collagen Synthesis in Myofibroblasts[J]. J Clin Exp Hepatol. 2017 Dec;7(4):316-320. [Content Brief]
- [3]. Gonzalez B, et al. Glycochenodeoxycholic acid (GCDC) induced hepatocyte apoptosis is associated with early modulation of intracellular PKC activity. Mol Cell Biochem. 2000 Apr;207(1-2):19-27. [Content Brief]
- [4]. Shi C, et al. Glycochenodeoxycholic acid induces stemness and chemoresistance via the STAT3 signaling pathway in hepatocellular carcinoma cells[J]. Aging (Albany NY). 2020 Aug 3;12(15):15546-15555. [Content Brief]
